Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 6/2021

01-12-2021 | Insulin Glargine | Bone and Diabetes (A Schwartz and P Vestergaard, Section Editors)

Effect of Newer Long-Acting Insulins on Hypoglycemia and Fracture Risk Among People with Diabetes: A Systematic Review

Authors: Stine Hangaard, Morten Hasselstrøm Jensen

Published in: Current Osteoporosis Reports | Issue 6/2021

Login to get access

Abstract

Purpose of Review

To investigate the effect of newer long-acting insulins on the risk of hypoglycemic episodes and fractures in people with diabetes.

Recent Findings

Hypoglycemic episodes are the critical limiting factor in glycemic management due to a deteriorating effect on quality of life. Hypoglycemia may in severe cases lead to unconsciousness and thus fractures. Newer long-acting insulins may result in more stable blood glucose levels, less hypoglycemic episodes, and reduced risk of fractures.

Summary

Use of insulin increases risk of hypoglycemic episodes, and hypoglycemic episodes increase risk of fractures plausible due to falls. Newer ultra-long-acting insulins reduce risk of hypoglycemic episodes compared to older alternatives, and they are thus promising for reducing fracture risk. However, more studies are needed to determine whether these new insulins reduce risk of fractures.
Literature
1.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:157.CrossRef
2.
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16.CrossRef
3.
4.
Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, Huang ES, Desai MM, Gill TM, Krumholz HM. National trends in US hospital admissions for hyperglycemia and hypoglycemia among medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174(7):1116–24.CrossRef
5.
Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;329(20):1437–41.CrossRef
6.
Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64(2):631-42
7.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.CrossRef
8.
Sejling A, Schouwenberg B, Faerch L, Thorsteinsson B, de Galan B, Pedersen-Bjergaard U. Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in people with Type 1 diabetes mellitus. Diabet Med. 2015;33(1):77–83.CrossRef
9.
American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28(5):1245–9.CrossRef
10.
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes - 2019. Diabetes Care. 2019;42(January):S61–70.CrossRef
11.
12.
Oyer DS. The science of hypoglycemia in patients with diabetes. Curr Diabetes Rev. 2013;9:195–208.CrossRef
13.
Bakatselos SO. Hypoglycemia unawareness. Diabetes Res Clin Pract. 2011;93(SUPPL. 1):S92–6.CrossRef
14.
Jensen MH, Vestergaard P. Hypoglycaemia and type 1 diabetes are associated with an increased risk of fractures. Osteoporos Int. 2019;30(8):1663–70.CrossRef
15.
16.
Van Dalem J, Brouwers MCGJ, Stehouwer CDA, Krings A, Leufkens HGM, Driessen JHM, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ. 2016;354:1–8.
17.
Jensen MH, Kjolby M, Hejlesen O, Jakobsen PE, Vestergaard P. Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: a cohort study of all danish users. Diabetes Care. 2020;43(6):1209–18.CrossRef
18.
Yale JF. Nocturnal hypoglycemia in patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2004;65(SUPPL):S41–6.CrossRef
19.
Strandberg AY, Khanfir H, Mäkimattila S, Saukkonen T, Strandberg TE, Hoti F. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults*. Ann Med. 2017;49(4):357–64.CrossRef
20.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis Diabetes Res Clin Pract. 2008;81(2):184–9.CrossRef
21.
Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, et al. Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7). Diabetes, Obes Metab [Internet]. 2019;21:1625–33 (March):1–9. Available from. https://​doi.​org/​10.​1111/​dom.​13699.CrossRef
22.
Jensen MH, Hejlesen O, Vestergaard P. Association of insulin regimens with severe hypoglycaemia in patients with type 1 diabetes: a Danish case–control study. Br J Clin Pharmacol. 2020;86(8):1560–6.CrossRef
23.
Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48(7):1292–9.CrossRef
24.•
Ntouva A, Toulis KA, Keerthy D, Adderley NJ, Hanif W, Thayakaran R, Gokhale K, Thomas GN, Khunti K, Tahrani AA, Nirantharakumar K. Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: a cohort study. Eur J Endocrinol. 2019;180(1):51–58
25.••
Hung YC, Lin CC, Chen HJ, Chang MP, Huang KC, Chen YH, Chen CC. Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study. Osteoporos Int. 2017;28(7):2053–60. A large cohort study using the Taiwan registries to identify risk of hip fracture as a function of people with or without hypoglycemic episodes leading to hospitalizationCrossRef
26.
27.
Lee RH, Sloane R, Pieper C, Lyles KW, Adler RA, Van Houtven C, et al. Glycemic control and insulin treatment alter fracture risk in older men with type 2 diabetes mellitus. J Bone Miner Res. 2019;34(11):2045–51.CrossRef
28.
Corrao G, Monzio Compagnoni M, Ronco R, Merlino L, Ciardullo S, Perseghin G, Banfi G. Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an increased fracture risk? Clin Orthop Relat Res. 2020;478(5):992–1003.CrossRef
29.••
Pscherer S, Kostev K, Dippel FW, Rathmann W. Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care. Diabetes, Metab Syndr Obes Targets Ther. 2016;9:17–23. This study provides a thorough investigation of the effect of different basal insulin compounds from human insulin to insulin analogues on the risk of fractures.
30.
Losada-Grande E, Hawley S, Soldevila B, Martinez-Laguna D, Nogues X, DIez-Perez A, et al. Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort analysis. Sci Rep. 2017;7(1):1–9.CrossRef
31.
Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R. A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naïve patients with type 2 diabetes mellitus. Drugs R D. 2016;16(2):239–49.CrossRef
32.
Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18(4):366–74.CrossRef
33.
Buse JB, Rodbard HW, Serrano CT, Luo J, Ivanyi T, Bue-Valleskey J, et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39(1):92–100.CrossRef
34.•
Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: results from SWITCH 2. Diabetes Obes Metab. 2019;21(7):1634–41. An interesting post hoc analysis of the well-designed double-blinded randomised controlled cross-over trial of T2D people prone to hypoglycemia switching between insulin degludec and insulin glargine U100CrossRef
35.
Shimoda S, Sato M, Sekigami T, Motoshima H, Yoshimura R, Fukuda K, Matsuo Y, Noda H, Okubo M, Ichimori S, Fujisawa K, Fukunaga M, Araki E, The Kumamoto Insulin Degludec Observational (KIDUNA) Study Group, Nishikawa T, Furukawa N, Matsumura T, Kondo T, Kawashima J, et al. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study). J Diabetes Investig. 2016;7(5):703–10.CrossRef
36.
Rasmussen NH, Dal J. Falls and fractures in diabetes—more than bone fragility. Curr Osteoporos Rep. 2019;17(3):147–56.CrossRef
Metadata
Title
Effect of Newer Long-Acting Insulins on Hypoglycemia and Fracture Risk Among People with Diabetes: A Systematic Review
Authors
Stine Hangaard
Morten Hasselstrøm Jensen
Publication date
01-12-2021
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 6/2021
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-021-00706-7

Other articles of this Issue 6/2021

Current Osteoporosis Reports 6/2021 Go to the issue

Biomechanics (J Nyman and C Hernandez, Section Editors)

Mechanobiology of Bone Metastatic Cancer

Kidney and Bone (IB Salusky and T Nickolas, Section Editors)

Peripheral Blood Mononuclear Cells (PBMCs) to Dissect the Underlying Mechanisms of Bone Disease in Chronic Kidney Disease and Rare Renal Diseases

Osteocytes (J Delgado-Calle and J Klein-Nulend, Section Editors)

Osteocytes and Estrogen Deficiency

Imaging (H Isaksson and S Boyd, Section Editors)

Statistical Shape and Appearance Models: Development Towards Improved Osteoporosis Care

Osteocytes (J Delgado-Calle and J Klein-Nulend, Section Editors)

Osteocytes and Cancer

Osteocytes (J Delgado-Calle and J Klein-Nulend, Section Editors)

The Osteocyte Transcriptome: Discovering Messages Buried Within Bone